课题基金 / 基金详情

Immuno and Epigenetics of Hematopoietic Cell Transplantation

Immuno and Epigenetics of Hematopoietic Cell Transplantation
造血细胞移植的免疫和表观遗传学
批准号:
10660131
负责人:
Effie W Petersdorf
金额:
$62.31万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-08-01 至 2028-04-30

项目摘要

项目成果

Effie W Petersdorf的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Hematopoietic cell transplantation from related and unrelated donors can cure life-threatening blood disorders; however, graft-versus-host disease (GVHD) and relapse remain the major obstacles. When matched donors are not available, the properties of that govern (un)favorable HLA mismatches are not well-defined. These deficiencies have important implications for a large fraction of patients who lack HLA-matched donors, and for all patients at risk for disease relapse. The advent of improved GVHD prevention regimens has increased the safety and efficacy of haploidentical transplantation and it is anticipated that its use in multi-locus mismatched unrelated transplantation will substantially increase options for patients. The unmet needs are to understand the mechanisms through which HLA-DR and -DQ genes modulate transplant risks, and a means to apply the research findings to clinical care. We have recently identified important features of HLA-DQ molecules and HLA-DR expression that describe (un)favorable mismatches, and they represent an entirely new paradigm for the HLA class II region. We propose to define the underlying mechanisms through which matched and mismatched HLA-DR and -DQ function in transplantation. The specific aims are to: determine the role of HLA- DQ structure and expression in outcome; determine the role of HLA-DRβ molecules in outcome; determine the impact of HLA-DR-DQ haplotype variation on clinical outcome after HLA-matched and -mismatched allogeneic transplantation, and design tools to translate class II features into clinical practice. The goals will be achieved through systemic analysis of HLA-DR and -DQ variation, peptide repertoire and expression in large ethnically diverse transplant populations with complete clinical data. This proposal will fill the knowledge gap in the immunobiological basis of GVHD, relapse and survivorship in transplantation. The information will increase the safety, efficacy and availability of transplantation for all patients in need of this life-saving therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunogenetics of Outcomes Disparities After Allogeneic HCT
  • 批准号:
    10659539
  • 项目类别:
  • 资助金额:
    $44.29万
  • 财政年份:
    2023
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
Immunogenetics of Outcomes Disparities after Allogeneic HCT
  • 批准号:
    10441227
  • 项目类别:
  • 资助金额:
    $39.45万
  • 财政年份:
    2018
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
  • 批准号:
    10601325
  • 项目类别:
  • 资助金额:
    $9.32万
  • 财政年份:
    2018
  • 负责人:
    Effie W Petersdorf
  • 依托单位:
海外基金